Hans Schikan is CEO of Prosensa, an innovative Dutch biopharmaceutical company focusing on the discovery, development and commercialization of novel treatments for rare diseases like Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease, using its RNA modulation platform. In 2009 Prosensa announced a key agreement with GlaxoSmithKline for part of its Duchenne compounds at a value of nearly USD 700 million. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles, including as Vice President for Global Marketing and Strategic Development of Genzyme’s portfolio of products for rare genetic diseases. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Next to his role at Prosensa, Hans is currently Executive Board Member of the Dutch Top Institute Pharma and Non-executive Director of Swedish Orphan Biovitrum. He is also past Chairman of Nefarma, the Dutch Association of Research Based Pharmaceutical Industry. He has a PharmD from Utrecht University.